Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327053 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT01327053 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 230 participants.
The verdict
NCT01327053, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
Interventions
- DRUG LDE225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2011-06-29 |
| Est. Completion | 2018-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327053
The ClinicalTrials.gov registry entry for NCT01327053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LDE225 is the first listed.
NCT01327053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327053 about?
NCT01327053 is a clinical study titled "A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma". This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
What is the current status of trial NCT01327053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2011-06-29. Estimated completion is 2018-06-29.
What interventions are being tested in trial NCT01327053?
The interventions under investigation include: LDE225 (DRUG).
Who is sponsoring clinical trial NCT01327053?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.